Regulatory Update For Qnexa Could Signal A Change In The Obesity Landscape
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
New developments for Vivus’ weight loss drug Qnexa may mean that the regulatory environment for obesity treatments could be improving.